A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
Dispenzieri A, Wiseman GA, Lacy MQ, Litzow MR, Anderson PM, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata L, Elliott MA, Lust JA, Greipp PR, Rajkumar SV, Fonseca R, Witzig TE, Erlichman C, Sloan JA, Gertz MA.
Dispenzieri A, et al. Among authors: ansell sm.
Leukemia. 2005 Jan;19(1):118-25. doi: 10.1038/sj.leu.2403575.
Leukemia. 2005.
PMID: 15526021
Clinical Trial.